Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2.

We have developed adenovector-based vaccines targeting G and M2 protein of respiratory syncytial virus. Single intranasal vaccination induced robust G protein-specific IgG and IgA responses, as well as M2-specific CD8 T-cell immunity, and provided protection against RSV A and B infection. These findings suggest that this vaccine combination holds promising potential for effective RSV prevention.